(0.06%) 5 540.25 points
(-0.10%) 39 488 points
(0.23%) 20 017 points
(0.93%) $81.58
(-2.10%) $2.70
(-0.42%) $2 321.00
(0.25%) $28.94
(1.24%) $998.60
(0.29%) $0.936
(0.19%) $10.62
(0.21%) $0.790
(-0.28%) $87.25
0.85% $ 3.56
Live Chart Being Loaded With Signals
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company\'s pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia...
Stats | |
---|---|
Tagesvolumen | 31 931 |
Durchschnittsvolumen | 35 256 |
Marktkapitalisierung | 19.53M |
EPS | $-0.660 ( Q3 | 2023-11-06 ) |
Last Dividend | $1 801.73 ( 1980-05-12 ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.270 (7.58%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-26 | Devall Christopher Franklin | Buy | 7 000 | Common Stock |
2023-12-26 | Wool Kyle Michael | Buy | 5 000 | Common Stock |
2023-12-21 | Wool Kyle Michael | Buy | 630 050 | Common Stock |
2023-12-20 | Hayes Anthony | Buy | 70 000 | Common Stock |
2023-12-12 | Hayes Anthony | Buy | 2 000 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 98 transactions |
Buy: 6 932 818 | Sell: 0 |
Volumen Korrelation
AIkido Pharma Inc. Korrelation
10 Am meisten positiv korreliert | |
---|---|
GNACW | 0.901 |
10 Am meisten negativ korreliert | |
---|---|
DAOO | -0.958 |
GNAC | -0.946 |
IIII | -0.935 |
SHQA | -0.911 |
SCOA | -0.905 |
HCIC | -0.901 |
HCII | -0.894 |
HIIIU | -0.883 |
HCICU | -0.851 |
HIII | -0.847 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
AIkido Pharma Inc. Korrelation - Währung/Rohstoff
AIkido Pharma Inc. Finanzdaten
Annual | 2022 |
Umsatz: | $0 |
Bruttogewinn: | $0 (0.00 %) |
EPS: | $-5.60 |
FY | 2022 |
Umsatz: | $0 |
Bruttogewinn: | $0 (0.00 %) |
EPS: | $-5.60 |
FY | 2021 |
Umsatz: | $0.00 |
Bruttogewinn: | $0.00 (0.00 %) |
EPS: | $-4.34 |
FY | 2020 |
Umsatz: | $0.00 |
Bruttogewinn: | $0.00 (0.00 %) |
EPS: | $-7.47 |
Financial Reports:
No articles found.
AIkido Pharma Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $1 544.34 | 1978-05-15 |
Last Dividend | $1 801.73 | 1980-05-12 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | $5 147.79 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.53 | -- |
Div. Sustainability Score | 1.053 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
1978 | $0 | 0.00% |
1979 | $0 | 0.00% |
1980 | $0 | 0.00% |
1981 | $0 | 0.00% |
1982 | $0 | 0.00% |
1983 | $0 | 0.00% |
1984 | $0 | 0.00% |
1985 | $0 | 0.00% |
1986 | $0 | 0.00% |
1987 | $0 | 0.00% |
1988 | $0 | 0.00% |
1989 | $0 | 0.00% |
1990 | $0 | 0.00% |
1991 | $0 | 0.00% |
1992 | $0 | 0.00% |
1993 | $0 | 0.00% |
1994 | $0 | 0.00% |
1995 | $0 | 0.00% |
1996 | $0 | 0.00% |
1997 | $0 | 0.00% |
1998 | $0 | 0.00% |
1999 | $0 | 0.00% |
2000 | $0 | 0.00% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0 | 0.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
12 May 1980 | $1 801.73 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
14 May 1979 | $1 801.73 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
15 May 1978 | $1 544.34 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -19.43 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.318 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.306 | 1.500 | -4.51 | -6.76 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 20.26 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 16.48 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.55 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00650 | -1.500 | 9.89 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 36.16 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -3.04 | 2.00 | -1.012 | -2.02 | [0 - 30] |
freeCashFlowPerShareTTM | -3.10 | 2.00 | -1.552 | -3.10 | [0 - 20] |
debtEquityRatioTTM | 0.00704 | -1.500 | 9.97 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 1.000 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -23.01 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -39.50 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0164 | 0.800 | -3.22 | -2.58 | [0.5 - 2] |
Total Score | 1.053 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.947 | 1.000 | -0.197 | 0 | [1 - 100] |
returnOnEquityTTM | -0.306 | 2.50 | -2.90 | -6.76 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -3.10 | 2.00 | -1.035 | -3.10 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -3.04 | 2.00 | -1.012 | -2.02 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0144 | 1.500 | -3.43 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -15.70 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.67 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
AIkido Pharma Inc.
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company\'s pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.